macitentan (Opsumit)
Jump to navigation
Jump to search
Indications
- pulmonary arterial hypertension (FDA-approved Oct 2013)
- may be of benefit in portopulmonary hypertension[2]
Contraindications
* female patients can receive the drug only through the Opsumit Risk Evaluation and Mitigation Strategy (REMS) Program
Dosage
Adverse effects
- anemia
- nasopharyngitis
- bronchitis
- headache
- flu-like symptoms or influenza
- urinary tract infection
Mechanism of action
More general terms
Component of
References
- ↑ FDA News Release: Oct. 18, 2013 FDA approves Opsumit to treat pulmonary arterial hypertension
- ↑ 2.0 2.1 2.2 Ingram I Opsumit Shows Promise in Portopulmonary Hypertension. Positive results in first randomized trial in the disease. MedPage Today. September 20, 2018 https://www.medpagetoday.com/meetingcoverage/ers/75206
Sitbon O, et al Efficacy and safety of macitentan in portopulmonary hypertension: The PORTICO trial. European Respiratory Society (ERS) 2018; Abstract OA267. - ↑ Actelion. MACITENTAN (Manufacturer's Information Page) http://www1.actelion.com/sites/en/scientists/development-pipeline/phase-3/macitentan.page